Related Experiment Video
Updated: Jul 31, 2026
05:52
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
RGS4 genotype is not associated with antipsychotic medication response in schizophrenia
O Kampman1, A Illi, K Hänninen
1Medical School, University of Tampere, Tampere, Finland. olli.kampman@uta.fi
Journal of Neural Transmission (Vienna, Austria : 1996)
|April 11, 2006
Summary
This study found no association between the RGS4 gene polymorphism (Rs 951436) and schizophrenia incidence, age at onset, or medication response in Finnish patients. The regulator of G-protein signaling 4 gene variant did not impact schizophrenia outcomes.
Area of Science:
- Neurogenetics
- Psychiatric disorders
- Molecular biology
Background:
- Schizophrenia is a complex psychiatric disorder with a significant genetic component.
- Investigating specific gene polymorphisms, such as single nucleotide polymorphisms (SNPs), is crucial for understanding schizophrenia's etiology.
- The regulator of G-protein signaling 4 (RGS4) gene has been implicated in neuronal function and may play a role in schizophrenia.
Observation:
- This study examined the allele frequencies of the RGS4 gene polymorphism (T > G, Rs 951436) in 219 Finnish schizophrenia patients and 389 controls.
- The study also analyzed genotype frequencies in relation to medication response in 93 schizophrenia patients and age at onset.
- The RGS4 (T > G, Rs 951436) genotype was assessed for its association with schizophrenia incidence, age at onset, and treatment outcomes.
Findings:
- The RGS4 (T > G, Rs 951436) genotype showed no statistically significant association with the incidence of schizophrenia in the Finnish population studied.
- No correlation was found between the RGS4 genotype and the age at onset of schizophrenia.
- Furthermore, the RGS4 genotype was not associated with medication response in the analyzed subpopulations of schizophrenia patients.
Implications:
- The findings suggest that the RGS4 gene polymorphism Rs 951436 may not be a significant genetic risk factor for schizophrenia in the Finnish population.
- This specific SNP does not appear to influence the clinical presentation of schizophrenia, including age at onset or response to medication.
- Further research into other genetic variations within or near the RGS4 gene, or in different populations, may be warranted to fully elucidate its role in schizophrenia.
More Related Videos
Related Concept Videos
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...